In the past ten years, big progress has been achieved in the treatment of LUAD with targeted lung cancer therapy such as drugs targeting the epidermal growth factor receptor (EGFR) mutation or the anaplastic lymphoma kinase (ALK)-rearranged NSCLC patients group [3]. Here, ALK is linked to non-small cell lung carcinoma.